ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,642,596 | +30.8% | 38,900 | +24.7% | 0.03% | +16.7% |
| Q2 2023 | $2,784,600 | +24.3% | 31,200 | +49.3% | 0.02% | +14.3% |
| Q1 2023 | $2,240,898 | -73.0% | 20,900 | -69.2% | 0.02% | -69.6% |
| Q4 2022 | $8,287,498 | +417.6% | 67,858 | +337.8% | 0.07% | +430.8% |
| Q3 2022 | $1,601,000 | -7.0% | 15,500 | +21.1% | 0.01% | -18.8% |
| Q4 2021 | $1,722,000 | -5.8% | 12,800 | -7.9% | 0.02% | -15.8% |
| Q2 2021 | $1,828,000 | +75.1% | 13,900 | +71.6% | 0.02% | +46.2% |
| Q1 2021 | $1,044,000 | -74.6% | 8,100 | -67.1% | 0.01% | -76.4% |
| Q4 2020 | $4,106,000 | -4.7% | 24,620 | -11.8% | 0.06% | -32.9% |
| Q3 2020 | $4,308,000 | +0.5% | 27,915 | -3.7% | 0.08% | +43.9% |
| Q2 2020 | $4,288,000 | +170.4% | 29,000 | +154.4% | 0.06% | +46.2% |
| Q4 2019 | $1,586,000 | -58.6% | 11,400 | -71.4% | 0.04% | -65.5% |
| Q3 2019 | $3,834,000 | -63.6% | 39,800 | -56.5% | 0.11% | -69.7% |
| Q2 2019 | $10,536,000 | -51.5% | 91,500 | -50.4% | 0.37% | -50.5% |
| Q1 2019 | $21,705,000 | +2077.0% | 184,400 | +1129.3% | 0.75% | +1296.3% |
| Q2 2018 | $997,000 | +181.6% | 15,000 | +53.6% | 0.05% | +68.8% |
| Q3 2017 | $354,000 | – | 9,763 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |